Joint BIA and Harwell Campus Networking Lunch


Accelerating development through multidisciplinary collaboration

This joint networking event, between BIA, Harwell Campus and Diamond Light Source, will bring together BIA members and Harwell Campus occupiers from the Space, HealthTec and EnergyTec clusters, as well as the wider bioscience community. This thought leadership event will focus on how collaboration across disciplines inside a rich and diverse life sciences ecosystem such as Harwell Campus can be a catalyst for innovation in research and discovery.

An eminent panel will discuss how the ‘cluster principle’ combined with multidisciplinary collaboration is finding solutions to key challenges more quickly, leading to shorter timescales to market and more rapid, successful scale-up for organisations.


Diamond House

11.00 – 11.30     Registration, tea and coffee; Showcase exhibition in the Diamond Atrium

Pickavance Theatre

11.40 – 11.50     Introduction, Harwell Campus update – Barbara Ghinelli

11.50 – 12.00     BIA update – Steve Bates

12.00  – 12.45    Panel discussion with Q & A

Diamond House

12.50 – 13.30     Lunch and networking + showcase exhibition

13.30 – 14.30     Optional tour of Diamond Light Source - separate sign-up required - email Alex


Barbara Ghinelli

Harwell Campus Business Development Director


Barbara oversees the development and management of clusters on the Harwell and Daresbury Campuses. She has established a high profile for the Space and the HealthTec Clusters and is leading the development of new Clusters including EnergyTec.

Barbara joined STFC in 2010 as Executive Director of Business Development. Successes included the creation of ISIC (now Satellite Application Catapult) at Harwell and of the High Performance Computing Centre (Hartree) at Daresbury.

Barbara joined STFC from EADS Astrium (now Airbus DS), where she managed Business Development across Europe for the €3.2 billion joint ESA / EU Earth Observation Programme for Global Monitoring of Environment and Security (now Copernicus) and secured a number of large contracts. She graduated in Electronic Engineering at the University of York, completed her PhD in Artificial Intelligence and Radar Imaging at the University of Sheffield and holds a Certificate in Management from the Open University

Steve Bates

Chief Executive Officer


Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.

A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.

Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.

Dr Hadrian Green

CEO and Director


Dr Green joined OxSyBio with more than a decade of experience working with global pharmaceutical and diagnostics companies as well as biotech companies and governments to drive the translation of science into next generation life-science businesses. This experience with Marakon Associates, Merck, GSK and Ernst & Young spans corporate and business unit strategy & transactions with a particular focus on personalised healthcare, clinical diagnostics, and small molecule and biological drug development. Hadrian graduated in Medicine and practiced across Australasia, the UK and several developing countries before earning a PhD in Molecular Imaging at the University of Cambridge in Molecular Imaging. Hadrian is a Fellow of the Cambridge Commonwealth Trust and was previously a bye-fellow of Queens’ College Cambridge.

Andy Hill

Director of Business Development

Oxford Academic Science Network

Andy is a life-sciences graduate and MBA with over 30 years’ experience in the medical technology industry as an executive and entrepreneur. His background is in sales, marketing and general management and he has a track record in the introduction of new and disruptive medical technologies into Europe and the USA. Andy has a particular interest in the creation and scaling of new technology businesses.

Andy built the European businesses (from first in human use to exit) for two US start-ups and has led businesses as a CEO in a diverse range of medical technology sectors, including interventional vascular, patient monitoring, imaging and AI. He cofounded and was a lead investor in an Oxford University spinout.

More recently, following a period consulting, Andy took responsibility for business development at the Oxford Academic Health Science Network (AHSN).

Nick Appleyard

Head of Downstream Business Applications

European Space Agency

Rhodri Davies

Senior Director of Production

Oxford Nanopore Technologies

Dr Nick Scott-Ram

VP Strategic and Commercial Development

Sensyne Health plc

Nick has over 25 years’ experience in commercial and business development in the life sciences sector, in particular in pharmaceuticals, diagnostics and digital health. He has an MA in Natural Sciences and a PhD in the Philosophy of Science from Cambridge University. He has worked in blue chip life science companies such as PowderJect Pharmaceuticals where he was VP Corporate Affairs, responsible for strategy, and Oxford BioMedica. Before joining Sensyne Health he was Director of Commercial Development at the Oxford AHSN where he was responsible for the development of strategic partnerships between industry, the NHS and academia.

He has extensive experience in commercial strategy, business development and in pharmaceutical pricing. He led the life sciences industry position on the Biotechnology Patents Directive through the European Parliament in the 1990s. He was awarded the MBE for services to biotechnology in 2001. He is a Director at the Oxford Martin School, University of Oxford and an Honorary Visiting Research Fellow in Medical Entrepreneurship at Oxford University.


Diamond Light Source

Harwell Campus, Didcot


OX11 0GD


Free for members and non members


Please note when registering for this event you are automatically agreeing to share your details with the communications team at Harwell Campus.

BIA Annual Supporters